儿童及青少年霍奇金淋巴瘤生存率的种族与民族差异:儿童肿瘤学组研究
该汇总分析纳入2002至2012年儿童肿瘤学组三项III期试验中1605例低、中、高危霍奇金淋巴瘤患者,比较非西班牙裔白人与非白人患者的生存。中位随访6.9年,无事件生存率无种族差异,但调整后非白人患者总生存风险更高(HR 1.88),主要归因于复发后死亡率升高。
要点
- 初治霍奇金淋巴瘤儿童无事件生存率无种族差异
- 调整后非白人患者总死亡风险为白人1.88倍(95%CI 1.1-3.3)
- 复发后5年生存:白人90%、非裔66%、西班牙裔80%
核心结论
- 当代儿童肿瘤学组试验中,初治霍奇金淋巴瘤无事件生存率无种族差异,但调整后非白人患者总生存更差,由复发后死亡增加驱动。
研究设计与样本
- 汇总分析纳入2002至2012年三项III期试验(AHOD0431低危、AHOD0031中危、AHOD0831高危)共1605例1岁以下至21岁患者。
主要发现
- 中位随访6.9年,累积复发率17%,5年无事件生存率83%(SE 1.2%),5年总生存率97%(SE <1%),均无种族差异。
- 多变量分析中非白人患者总死亡风险比为1.88(95%CI 1.1-3.3)。
- 复发后5年生存率:非西班牙裔白人90%、非裔66%、西班牙裔80%(P<.01)。
- 相比白人,西班牙裔和非裔复发后死亡风险比分别为2.7(95%CI 1.2-6.2)和3.5(95%CI 1.5-8.2)。
临床怎么用
- 临床应关注非白人霍奇金淋巴瘤患儿复发后的生存差异,加强复发后管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Population-based studies of children and adolescents with Hodgkin lymphoma (HL) report a survival disadvantage in nonwhite-non-Hispanic black (NHB) and Hispanic-patients. Whether disparities persist after adjustment for clinical and treatment-related variables is unknown. We examined survival by race/ethnicity in children receiving risk-based, response-adapted, combined-modality therapy for HL in contemporary Children's Oncology Group trials. PATIENTS AND METHODS: This pooled analysis used individual-level data from 1,605 patients (younger than age 1 to 21 years) enrolled in phase III trials for low-risk (AHOD0431), intermediate-risk (AHOD0031), and high-risk (AHOD0831) HL from 2002 to 2012. Event-free survival (EFS) and overall survival (OS) were compared between non-Hispanic white (NHW) and nonwhite patients. Cox proportional hazards for survival were estimated for both de novo and relapsed HL, adjusting for demographics, disease characteristics, and therapy. RESULTS: At median follow up of 6.9 years, cumulative incidence of relapse was 17%. Unadjusted 5-year EFS and OS were 83% (SE, 1.2%) and 97% (SE, < 1%), respectively. Neither differed by race/ethnicity. In multivariable analyses for OS, nonwhite patients had a 1.88× higher hazard of death (95% CI, 1.1 to 3.3). Five-year postrelapse survival probabilities by race were as follows: NHW, 90%; NHB, 66%; and Hispanic, 80% (P < .01). Compared with NHW, Hispanic and NHB children had 2.7-fold (95% CI, 1.2 to 6.2) and 3.5-fold (95% CI, 1.5 to 8.2) higher hazard of postrelapse mortality, respectively. CONCLUSION: In patients who were treated for de novo HL in contemporary Children's Oncology Group trials, EFS did not differ by race/ethnicity; however, adjusted OS was significantly worse in nonwhite patients, a finding driven by increased postrelapse mortality in this population. Additional studies examining treatment and survival disparities after relapse are warranted.
引用
- Kahn JM, Kelly KM, Pei Q, et al. Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study. J Clin Oncol. 2019. PMID: 31539308. doi:10.1200/JCO.19.00812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。